TY - JOUR
T1 - Respiratory ATP synthesis: the new generation of mycobacterial drug targets?
AU - Bald, D.
AU - Koul, A.
PY - 2010
Y1 - 2010
N2 - Mycobacterium tuberculosis, the causative agent of tuberculosis, poses a global health challenge due to the emergence of drug-resistant strains. Recently, bacterial energy metabolism has come into focus as a promising new target pathway for the development of antimycobacterial drugs. This review summarizes our current knowledge on mycobacterial respiratory energy conversion, in particular, during the physiologically dormant state that is associated with latent or persistent tuberculosis infections. Targeting components of respiratory ATP production, such as type-2 NADH dehydrogenase or ATP synthase, is illustrated as an emerging strategy in the development of novel drugs. © 2010 Federation of European Microbiological Societies. Published by Blackwell Publishing Ltd.
AB - Mycobacterium tuberculosis, the causative agent of tuberculosis, poses a global health challenge due to the emergence of drug-resistant strains. Recently, bacterial energy metabolism has come into focus as a promising new target pathway for the development of antimycobacterial drugs. This review summarizes our current knowledge on mycobacterial respiratory energy conversion, in particular, during the physiologically dormant state that is associated with latent or persistent tuberculosis infections. Targeting components of respiratory ATP production, such as type-2 NADH dehydrogenase or ATP synthase, is illustrated as an emerging strategy in the development of novel drugs. © 2010 Federation of European Microbiological Societies. Published by Blackwell Publishing Ltd.
U2 - 10.1111/j.1574-6968.2010.01959.x
DO - 10.1111/j.1574-6968.2010.01959.x
M3 - Article
SN - 0378-1097
VL - 308
SP - 1
EP - 7
JO - FEMS Microbiology Letters
JF - FEMS Microbiology Letters
ER -